Exousia Bio (LMMY) stock price is $0.02, unchanged on the day, as of Oct 14, 2026. It has a market cap of $239.74K, and is classified in the Education Technology industry (Technology sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap239,736.17
P/E-2.42
Div. Yield0.00
Add ratio to table…
About
Exousia Bio, Inc. is a startup incorporated in Wyoming in January 2022 that focuses on delivering financial education to children. The Company’s Registration Statement on Form S-1 was declared effective by the SEC on February 13, 2023, followed by an initial public offering that concluded in May 2023. In December 2024, a change in control occurred when Zhang Shengwu acquired approximately 67.51% of the outstanding shares, gaining voting control of the company. Following…
Exousia Bio, Inc. is a startup incorporated in Wyoming in January 2022 that focuses on delivering financial education to children. The Company’s Registration Statement on Form S-1 was declared effective by the SEC on February 13, 2023, followed by an initial public offering that concluded in May 2023. In December 2024, a change in control occurred when Zhang Shengwu acquired approximately 67.51% of the outstanding shares, gaining voting control of the company. Following this transaction, Zhang Shengwu was appointed as the sole director, president, chief executive officer and secretary, while prior officers resigned. The company’s primary product is an educational platform and a video game marketed as twoplus1® that combines eLearning and gaming to teach financial knowledge and resource management. The product is designed to deliver an immersive learning experience in finance and real estate through a competitive subscription fee. Exousia Bio, Inc. operates at the intersection of the edtech and gaming industries, targeting a niche market of young learners.
Revenue is generated mainly through subscription fees charged for access to the twoplus1® platform. The subscription model is designed to be competitively priced to attract a broad base of individual users and families. Additionally, the company plans to earn commissions from virtual property transactions that users can conduct within the game environment. These revenue-generating features are integrated into the gameplay to monetize user activity without relying on advertisements. No government approvals are required for the core products or services offered by the company. The business model emphasizes the use of new technologies and innovative approaches to reduce costs while enhancing user engagement.
Exousia Bio, Inc. positions itself as a nimble competitor in the crowded edtech and gaming landscapes. The company emphasizes low startup costs, rapid deployment, and close proximity to its customer base as advantages over larger, more established firms. These factors lower the barrier to entering the narrow niche of numerous competitors that serve the same target markets. By focusing on the specific intersection of financial literacy and interactive gaming, the company seeks to carve out a defensible niche. Its strategy leverages technological innovation to improve learning outcomes and differentiate its offering from traditional educational products. The company has secured trademark protection for the twoplus1® brand in the United Kingdom and is pursuing similar protection in other key regions.
The company’s customers are primarily children who engage with the twoplus1® game to learn about money management, investing, and real estate concepts. Parents and guardians also constitute an important segment of the user base, as they seek educational tools that are both entertaining and instructive for their children. The platform is accessible online, allowing reach to users across geographic locations without the need for localized regulatory clearance. No specific customer names are disclosed in the filing. The company reports that it has not suffered any bankruptcy, receivership or similar proceeding, and there have been no material reclassifications, mergers, consolidations or significant asset transactions outside the ordinary course of business.
Sector:TechnologySector rationaleThe company's primary revenue is generated through subscription fees for twoplus1®, which is described as an educational platform and video game (EdTech and gaming). This falls under Technology as it is a software-based product (Education Technology and Video Games). A secondary sector of Consumer Discretionary is appropriate because the product is marketed as a video game for children, which is a non-essential entertainment experience.Industries:Education TechnologyEducation TechnologyPrimaryExousia Bio provides an educational platform called twoplus1® designed to teach children financial knowledge and resource management. Revenue is generated through subscription fees charged to individual users and families for access to this eLearning platform.Video GamesVideo GamesSecondaryThe company's primary product is a video game that combines gaming with education to deliver an immersive learning experience. The business model includes earning commissions from virtual property transactions conducted within the game environment.Classified using BQ-MICSCIK: 0001939937
Peer percentiles
How Exousia Bio ranks
Ranked against the 99 companies in Vertical Software·58 metrics · as of Oct 16, 2026
Valuation
12 metrics · Lower multiples rank higher; a negative multiple ranks last
WorseBetterPeer median
P/ENegative earnings−3.38xMedian 40.2x32nd
P/FCF3.95xMedian 18.5x96th
P/Operating cash flow3.92xMedian 17.5x93rd
P/S—Median 2.60xNo data—
P/B0.02xMedian 1.84x99th
P/Tangible book0.02xMedian 2.34x99th
EV/EBITDANegative EBITDA−1.37xMedian 18.6x11th
EV/EBITNegative EBIT−0.63xMedian 30.9x7th
EV/Revenue—Median 2.98xNo data—
EV/FCF3.95xMedian 19.8x99th
EV/Operating cash flow3.92xMedian 18.2x99th
PEG (3Y EPS CAGR)—Median 1.60No data—
Growth
14 metrics · Year-on-year growth and three-year compound annual growth
WorseBetterPeer median
Revenue growth (1Y)—Median 10.8%No data—
Revenue CAGR (3Y)—Median 9.9%No data—
Gross profit growth (1Y)−5,967%Median 10.3%1st
Gross profit CAGR (3Y)—Median 10.9%No data—
Operating income growth (1Y)<−10,000%Median 17.1%1st